72 results about "Corneal endothelial cell" patented technology

Provided are compositions comprising aggregates of corneal endothelial cells (CECs) and methods administering said aggregates to patients for the treatment of corneal endothelial disease.

The utility model discloses a cornea negative pressure suction trephine device for an eye library, which is a device for obtaining a cornea graft from an eyeball of a donor, and comprises an adsorption ring which is positioned on the eyeball above the cornea and a trephine which is sleeved on the periphery of the adsorption ring and can rotate relative to the adsorption ring, an annular adsorption face capable of being adsorbed to the eyeball in a negative pressure suction mode is formed on the end face of the adsorption ring, the trephine comprises a circular ring component and a circular cutting part formed at the far end of the circular ring component and used for annularly cutting the sclera, and the circular ring component is arranged on the periphery of the end, close to the annular adsorption face, of the adsorption ring in a sleeving mode. Thus, the cornea acquisition negative pressure suction trephine device for the eye library can be provided, the cornea acquisition negative pressure suction trephine device for the eye library is suitable for acquiring a cornea graft with uniform sclera tissue from a donor in a rotary cutting mode, and extrusion damage to cornea endothelial cells can be effectively reduced.

The invention discloses application of ganoderma lucidum exosomes in preparation of corneal injury repair preparations, and belongs to the technical field of biological medicines. The ganoderma lucidum exosome realizes corneal injury repair by promoting corneal endothelial cell proliferation and migration ability, promotes corneal endothelial proliferation and cell migration and accelerates corneal endothelial injury repair through an EGFR / ERK signal channel, can be used for treatment of corneal epithelium defect related ocular surface diseases, corneal lesion and other diseases, and has a wide application prospect. And a new thought is provided for treatment of corneal endothelial diseases.

The invention discloses a corneal endothelial cell protection liquid for reducing corneal endothelial cell metabolism, which takes dextran or a combination of dextran and chondroitin sulfate as a dehydrating agent, takes beta-hydroxybutyric acid and dexmedetomidine as antioxidants, and simultaneously contains two buffer systems of sodium bicarbonate and HEPES. According to the invention, the metabolism of corneal endothelial cells can be reduced, and the form of the corneal endothelial cells in vitro can be better maintained.

The invention provides application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy, and particularly belongs to the technical field of medicine preparation. The invention provides an application of taurochenodeoxycholic acid in preparation of a medicine for preventing and / or treating Fuchs corneal endothelial dystrophy. Test results show that taurochenodeoxycholic acid can realize prevention and / or treatment of corneal endothelial cell injury caused by UVA; the number reduction, activity reduction, oxidative stress, ROS level rise and mitochondrial membrane potential drop of corneal endothelial cells caused by UVA are relieved; mitochondrial biological energy deficiency caused by UVA is relieved; and the prevention and / or treatment of the Fuchs corneal endothelial dystrophy are / is realized by activating a Ca < 2 + > signal channel.

To provide an agent for modulating expression of extracellular matrix by corneal endothelial cells.SOLUTION: The present invention pertains to an agent for modulating expression of extracellular matrix by corneal endothelial cells, containing 1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof, or a solvate thereof.SELECTED DRAWING: None

The utility model relates to the field of medical instruments, in particular to an eye microneedle cornea patch structure and a mold for preparing an eye microneedle cornea patch, which can prevent a microneedle on a microneedle substrate from damaging a cornea sclera marginal structure and cornea endothelial cells and further reduce damage to eyes of a patient in microneedle treatment. Comprising a microneedle substrate matched with an eyeball contour curved surface, a microneedle is arranged on the inner side wall face of the microneedle substrate and extends in the direction perpendicular to the inner side wall face of the microneedle substrate, a substrate through hole is formed in the geometric center of the microneedle substrate, the diameter of the microneedle substrate is smaller than that of a cornea, the diameter of the substrate through hole is not smaller than 4 mm, and the diameter of the substrate through hole is larger than or equal to 5 mm. And the microneedles are uniformly arranged on the microneedle substrate around the substrate through hole.

The invention discloses a corneal endothelial cell meter light path system and a corneal endothelial cell meter, and relates to the technical field of ophthalmology medical equipment.The corneal endothelial cell meter light path system comprises a first optical branch, a first auxiliary branch, a second optical branch and a second auxiliary branch; the first optical branch is used for corneal endothelial cell imaging; the first auxiliary branch and the first optical branch are symmetrically arranged, and the first auxiliary branch is used for providing a light source when the first optical branch is used for corneal endothelial cell imaging; the second optical branch is used for measuring the cornea thickness; and the second auxiliary branch is used for assisting the second optical branch in measuring the cornea thickness and positioning the Z axis of the human eye. According to the technical scheme, the optical path system of the corneal endothelial cell meter can be used for imaging the cornea and measuring the thickness of the cornea through optical path arrangement of the first optical branch, the first auxiliary branch, the second optical branch and the second auxiliary branch, the cornea and the thickness of the cornea do not interfere with each other and can be measured at the same time, and the optical path system is low in installation and adjustment difficulty and easy to develop.

The present invention provides a method for determining the quality of cultured corneal endothelial cells (CECs) comprising measuring in or on a cultured CEC a level of expression of the genes Thrombospondin-2 (THBS2) and / or Vitelline Membrane Outer Layer 1 Homolog (VMO1), and determining that the quality of said cultured CEC is non-therapy-grade if said measured level of expression corresponds to a THBS2+ and / or VMO1+ expression profile.

The present invention aims to provide a cell inoculum and a cell transplantation substrate which can be subcultured without causing cell transformation and can effectively implant cells. An inoculum and a transplantation substrate containing a phenolphthalein derivative for facilitating implantation of cultured corneal endothelial cells or corneal endothelial replacement cells. The inoculum and the transplantation substrate can facilitate adhesion of cells during subculture and implantation of cells during transplantation.

The present invention discloses an intraocular irrigation solution containing niacinamide. Niacinamide serves as an active substance in the intraocular irrigation solution, which has the effects of improving the function of corneal endothelial cells, inhibiting cell apoptosis and cell fusion, and improving the mitochondrial damage condition, thereby alleviating or inhibiting corneal edema, reduction of corneal endothelial cells, abnormal corneal transparency, abnormal corneal thickness, abnormal corneal endothelial cell density, abnormal corneal endothelial cell morphology, and abnormal expression of corneal endothelial cell functional proteins caused by ultrasonic stimulation, heat stimulation or oxidative damage to corneal endothelial cells during phacoemulsification surgery.

The present disclosure provides a method for cryopreserving corneal endothelial cells and / or corneal endothelial-like cells, and a freezing prepartaion for corneal endothelial cells and / or corneal endothelial-like cells. The present disclosure provides a method for preserving corneal endothelial cells and / or corneal endothelial-like cells, wherein the method includes: a freezing step for freezing unfrozen corneal endothelial cells and / or corneal endothelial-like cells, the freezing step including at least one stage in which the temperature is reduced at a rate of less than 1°C / min when the temperature is changed from the unfrozen temperature to the freezing target temperature; and, if necessary, a step for maintaining the corneal endothelial cells and / or the corneal endothelial-like cells in a frozen state.

A nicotinamide-containing intraocular surgery perfusate, a preparation method therefor, and use thereof. Use of nicotinamide in an intraocular surgery perfusate. The intraocular surgery perfusate improved using nicotinamide can inhibit corneal endothelial cell damage caused by cataract ultrasonic emulsification surgery treatment, relieve corneal edema caused by cataract ultrasonic emulsification surgery, prevent the number of corneal endothelial cells from being significantly reduced due to surgery, promote the postsurgical recovery of corneal transparency, promote the recovery of the thickness of the cornea to a normal level, maintain the normal density and cellular morphology of the corneal endothelial cells and the regular expression of functional proteins, and reduce complications caused by cataract ultrasonic emulsification surgery. The present invention can provide an effective strategy for the rapid postsurgical recovery of normal visual function in cataract patients.

Congenital hereditary endothelial dystrophy (CHED) is an autosomal recessive condition affecting the corneal endothelial cells, which function to maintain corneal clarity. Currently there is no highly efficacious treatment available for CHED caused by SLC4A11 gene mutations. The invention disclosed herein includes mammalian vectors for use in the treatment of Congenital hereditary endothelial dystrophy and methods for using such vectors.

To provide a method for producing corneal endothelial substitute cells to which novel functionality has been imparted, particularly a method for producing corneal endothelial substitute cells derived from iPS cells.SOLUTION: A method for producing functionalized corneal endothelial substitute cells is provided, comprising the steps of: introducing a nucleic acid encoding a functional molecule into the genome of a pluripotent stem cell; and inducing the pluripotent stem cell containing the introduced nucleic acid into a corneal endothelial substitute cell.SELECTED DRAWING: None

The present application relates to the technical field of medical data processing, in particular to a cataract ultrasonic emulsification postoperative corneal rehabilitation evaluation system based on deep learning. The system comprises an image acquisition module for acquiring postoperative corneal endothelial cell images of a person; a first abnormality analysis module for extracting abnormal corneal regions in the corneal endothelial cell images; a second abnormality analysis module for screening out suspected mechanical damage regions from the abnormal corneal regions; a region segmentation module for segmenting the suspected mechanical damage regions into suspected damage sub-regions; a region division module for determining the division parameters of the suspected damage sub-regions belonging to mechanical damage; based on the pixel number, area and corresponding division parameters in the suspected damage sub-regions, determining the rehabilitation degree, and dividing the suspected damage sub-regions into mechanical damage regions and hyperglycemia damage regions. The present application improves the accuracy of segmentation of mechanical damage regions and hyperglycemia damage regions.

The present invention relates to the use of corneal cell-derived mitochondria for the prevention or treatment of corneal damage or corneal endothelial cell diseases. It has been confirmed that mitochondria isolated from corneal endothelial cells differentiated from induced pluripotent stem cells (iPSCs) of the present invention alleviate the inflammatory response of corneal endothelial cells in an inflammatory environment, restore the integrity and function of corneal endothelial cells, and, when delivered into heterologous primary corneal endothelial cells, suppress inflammatory responses, particularly inflammation caused by physical damage, and promote the regeneration of corneal endothelial cells. Therefore, mitochondria possessing such effects can overcome the tumorigenic limitations of conventional stem cell therapies, and due to their ease of production and minimal regulatory requirements, they offer excellent cost-effectiveness and broad applicability.

1. Name of the product in this design: Corneal endothelial cell counter. 2. Purpose of this design: This design is used as an ophthalmic device for evaluating the density, morphology and function of corneal endothelial cells. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model.

The present invention relates to the field of biomedical technologies, and particularly to the application of fenofibrate in the treatment of Fuchs endothelial corneal dystrophy. By using the fenofibrate drug, the present invention can effectively reduce the thickness of Descemet's membrane during the pathogenesis of FECD, reduce the decrease in corneal endothelial cell density, cell damage, etc., and ultimately improve corneal endothelial decompensation.

The invention relates to a cornea layering fixator which solves the problem that an existing cornea layering fixator is inconvenient to use. The supporting seat is of a sleeve-shaped structure, a supporting table is arranged at the top of the supporting seat, the periphery of the supporting seat is sleeved with the pressing piece, a cornea pressing edge is arranged on the pressing piece, a center hole allowing a cornea endothelial cell layer to be exposed is formed in the middle of the pressing piece, and the pressing piece and the supporting seat are fixed through the fastening piece; the jacking column is movably connected with the inner wall of the sleeve of the supporting base, and an arc protrusion is arranged at the top of the jacking column. During use, the concave surface of the edge of a cornea is placed on the supporting table of the supporting seat upwards, then the supporting seat is sleeved with the pressing piece, the edge of the cornea is pressed by the cornea pressing edge, then the pressing piece and the supporting seat are fixed through the fastening piece, and then the jacking column moves upwards from the interior of the sleeve of the supporting seat to jack the cornea and then fix the cornea. At the moment, the inward concave surface of the cornea in the original state is changed into an upward-protruding arc surface, so that a doctor can perform layered operation conveniently, and use is convenient.

The present invention relates to a sulfanon derivative or a pharmaceutically acceptable salt thereof, and a composition for cancer prevention or treatment containing the derivative as an active ingredient. The sulfanon derivative or a pharmaceutically acceptable salt thereof of the present invention has excellent Nrf2 activation effect, high solubility and drug metabolic stability, anti-inflammatory and antioxidant effects, and improves exercise ability and cognitive ability. Therefore, it is used for the prevention or treatment of diseases induced by the decrease of Nrf2 activity, preferably liver diseases, kidney diseases, lung diseases, neurodegenerative diseases, mitochondrial myopathy, Friedreich's ataxia, corneal endothelial cell reduction, and psoriasis.

To provide means capable of efficiently proliferating a corneal endothelial cell, and means for stably supplying corneal endothelium preparation.SOLUTION: There are provided an adhesion promoter for a corneal endothelial cell which contains an Rho kinase inhibitor, culture solution of a corneal endothelial cell which contains an Rho kinase inhibitor, cornea preservation solution which contains an Rho kinase inhibitor, a manufacturing method of a corneal endothelium preparation which includes a process of culturing a corneal endothelial cell by using the culture solution, and a corneal endothelium protective agent which contains an Rho kinase inhibitor. The adhesion promoter for a corneal endothelial cell of the present invention promotes adhesion of the corneal endothelial cell, and enables formation of a corneal endothelial cell layer having a satisfactory cell morphology and high cell density.SELECTED DRAWING: None

Human embryonic stem cell (hESC)- and induced pluripotent stem cell (iPSC)-derived clinical-grade corneal endothelial cells (CECs) generation and cryopreservation through the neural crest cell (NCC) lineage using peripheral blood as a donor source and hESCs maximizes the availability of these vital cells for treating the corneal endothelial disease as an alternative to donor corneas for corneal endothelium (CE) transplantations and other applications.

The present invention refers to an in vitro or ex vivo method for reversing and / or reducing and / or inhibiting the endothelial to mesenchymal transition (EnMT) process in corneal endothelial cells, preferably in primary and / or human corneal endothelial cells, more preferably primary human corneal endothelial cells (HCEnCs), said method comprising the step of incubating said cells with at least one inhibitor of glycogen synthase kinase 3 (GSK-3).

The present disclosure provides: a method for washing corneal endothelial cells; and a method for producing a corneal endothelial cell preparation. In one aspect, the present disclosure provides a method for producing a corneal endothelial cell preparation, the method comprising a step for washing a corneal endothelial cell or a corneal endothelium-like cell with a solution containing about 0.01% by weight to about 10% by weight of a protein and a step for mixing the corneal endothelial cell or the corneal endothelium-like cell with a composition for preparation production use to produce a corneal endothelial preparation, in which the protein is selected from the group consisting of human serum albumin, casein, lactoferrin, ovalbumin, and combinations thereof.

The utility model provides a cornea preservation device which comprises the following components: a main box body which comprises a first liquid storage cavity and a bracket, the bracket is provided with an arc-shaped groove, the arc-shaped groove is provided with a communicating hole, and the outer side surface of a cornea in the arc-shaped groove is in contact with liquid in the first liquid storage cavity through the communicating hole; the upper box body comprises a second liquid storage cavity with a bottom opening and an elastic film surrounding the bottom opening, the bottom of the elastic film is matched with the shape of the edge of the inner side surface of the cornea to be stored, and the upper box body is arranged above the bracket in the mode that the elastic film is attached to the edge of the inner side surface of the cornea to be stored in the arc-shaped groove; and the inner side surface of the cornea to be preserved in the arc-shaped groove is in contact with the liquid in the second liquid storage cavity through the bottom opening. According to the utility model, the inner side surface and the outer side surface of the cornea can be respectively contacted with different liquids, so that the time for keeping the activity of in-vitro corneal endothelial cells is prolonged.

To provide a method for producing a cultured human corneal endothelial cell useful for an extremely long period of time for improving corneal opacity and hydration edema of a patient with corneal endothelial dysfunction.SOLUTION: A method for producing a human functional corneal endothelial cell capable of inducing a human corneal function when injected into an anterior chamber of a human eye, comprising (b) a step of proliferating and / or differentiating / maturing a corneal endothelial progenitor cell under a culture condition capable of minimizing culture stress such as proliferation stress.SELECTED DRAWING: None